89

Long-acting growth hormone in children: what remains uncertain?. Synthesize the consensus and related evidence around which pediatric patients may benefit from long-acting growth hormone and why adherence matters. Separate practical considerations from evidence gaps, especially long-term efficacy, safety, real-world follow-up, and concerns about weekly exposure profiles.

Long-acting growth hormone in children: current consensus and where it fits

The current consensus is that long-acting growth hormone (LAGH) is a meaningful once-weekly alternative to daily recombinant human growth hormone for children with growth hormone deficiency, with phase 3 trials showing non-inferior efficacy and similar short-term safety, while guidelines and best-practice use are still evolving.[1][2]

The main clinical message from the attached sources is not that weekly therapy is universally better, but that it may be most useful when the main barrier to success is adherence to daily injections. The sources repeatedly emphasize patient selection as critical.[3]

  • Most likely to benefit: children at risk of poor adherence to daily injections, including those with needle phobia or behavioral difficulties, very young children and adolescents, children receiving multidrug therapy, and families facing practical barriers such as separated households, frequent travel, or structured activities that disrupt daily routines.[4]
  • Why adherence matters: daily injection burden, pain, storage needs, and travel inconvenience are linked to poor compliance, so a weekly option may improve persistence and quality of life when these barriers are the main obstacle.[5]
  • Practical note: LAGH should be selected carefully rather than used as a default, because the sources frame it as a tool for specific patients, not a blanket replacement for daily therapy.[6]

Evidence-supported benefits and practical considerations

The attached sources support a pragmatic view: LAGH can reduce treatment burden and may improve real-world adherence, which is clinically important because growth hormone therapy depends on sustained use over time.[7]

  • Potential practical advantages: fewer injections, less day-to-day disruption, and possibly better acceptance in children and families who struggle with daily treatment.[8]
  • Clinical caution points: altered pharmacodynamics, lack of pulsatile secretion, and possible antibody formation should be kept in mind when counseling families and choosing a product.[9]
  • Formulation-specific issue: lipoatrophy at the injection site is a concern, especially with PEGylated formulations.[10]
  • Indications caution: these therapies are not yet approved for other conditions traditionally treated with daily rhGH, such as Turner or Noonan syndrome, so use should stay aligned with current approvals and evidence.[11]

Evidence gaps and unresolved safety questions

The biggest limitations are long-term rather than short-term. The sources agree that trial data are encouraging, but they also stress that more research and real-world follow-up are still needed to define long-term efficacy, broader safety, and durability of benefit after the trial setting.[12][13]

A central concern is the weekly exposure profile itself. Weekly dosing creates a non-physiological growth hormone pattern because it lacks pulsatile secretion and produces weekly rather than daily peaks, and the long-term implications of that altered exposure remain uncertain.[14][15]

  • Short-term trial safety looks similar to daily therapy, but the evidence base is still maturing.[16]
  • Long-term safety remains less certain, especially for effects that may only appear after prolonged exposure or broader post-trial use.[17][18]
  • Real-world registry and post-marketing follow-up are needed to understand persistence, selection patterns, and outcomes outside tightly controlled trials.[19][20]

Bottom line

In children with growth hormone deficiency, LAGH is best viewed as a targeted adherence solution for selected patients who are unlikely to do well with daily injections, rather than a universally preferred option. The evidence supports short-term efficacy and acceptable safety, but long-term efficacy, long-term safety, real-world follow-up, and the implications of weekly non-physiological exposure remain important evidence gaps.[21][22][23][24]


Related Content From The Pandipedia